Company Filing History:
Years Active: 2017-2018
Title: Sandro Colagioia: Innovator in TRPM8 Antagonists
Introduction
Sandro Colagioia is a notable inventor based in L'Aquila, Italy. He has made significant contributions to the field of pharmacology, particularly through his work on TRPM8 antagonists. With a total of two patents to his name, Colagioia's inventions are aimed at addressing various medical conditions.
Latest Patents
Colagioia's latest patents focus on compounds that act as selective antagonists of the Transient Receptor Potential cation channel subfamily M member 8 (TRPM8). These compounds are designed to be useful in the treatment of diseases associated with TRPM8 activity, including pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, and respiratory disorders exacerbated by cold. The innovative nature of these compounds highlights their potential in advancing therapeutic options for patients suffering from these conditions.
Career Highlights
Colagioia is currently associated with Dompé Farmaceutici S.p.a., a company known for its commitment to research and development in the pharmaceutical sector. His work at Dompé has allowed him to focus on groundbreaking research that has the potential to improve patient outcomes.
Collaborations
Throughout his career, Colagioia has collaborated with talented individuals such as Alessio Moriconi and Gianluca Bianchini. These collaborations have fostered an environment of innovation and creativity, contributing to the success of their projects.
Conclusion
Sandro Colagioia is a prominent figure in the field of pharmacology, with a focus on TRPM8 antagonists that hold promise for treating various medical conditions. His contributions through patents and collaborations underscore his commitment to advancing medical science.